John Muscedere

@muscedej

Intensivist, Professor of Medicine at Queen's. SD of the Canadian Frailty Network. Research interests include improving ICU outcomes, VAP and healthy aging.

Kingston, Ontario Canada Joined May 2014

105 Following 356 Followers 219 Posts

Latest posts 5

John Muscedere @muscedej Mar 27

Our frailty summit manuscript is available, open access, in Chest Critical Care
kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

With aging populations, there are ever increasing numbers of critically ill frail persons. Filling existing knowledge gaps such that we can improve care is paramount.

John Muscedere @muscedej Jan 29

Thank you to all the participants for your valuable insights, contributions, and help in getting this published. Hopefully, the research gaps highlighted can be addressed soon to improve care for critically ill frail patients.

Hayley Gershengorn @HBGMD Jan 29

Amazing things happen when 3️⃣2️⃣ ICU frailty experts get together!

✔️ out the new ✳️Special Feature✳️ in #journal_CHESTCritCare outlining their consensus on research priorities for the field:

chestcc.org/article/S2949-…

Thx, @muscedej, for leading this great effort!

#OpenAccess

View quoted post on X

John Muscedere @muscedej Jul 24, 2025

To advance Geroscience, we need to develop regulatory frameworks, to refine methodology and to address public perception. See this recent study. authors.elsevier.com/sd/article/S12…
Thanks to all co-authors @DrGustavoDuque @RollandYves2 @GeriSciDoc @brunovellas @carrieshorey @reshmaamerchant

John Muscedere @muscedej Sep 15, 2024

Thanks to all the attendees and for the great discussion. There is a pressing need to understand more about frailty in the critically and how to improve patient centered outcomes.

Bram Rochwerg @Bram_Rochwerg Sep 15, 2024

Frailty in ICU Summit, Vancouver. Great exchange of knowledge and discussion of ideas for future interventions and research. Thanks @muscedej for the invite. @CFN_NCE

View quoted post on X

John Muscedere @muscedej Aug 15, 2024

Thank you to @CIHR_IRSC ACT competition for funding a Phase 3 trial of inhaled furosemide as supportive therapy for resp. failure 2nd to pulmonary infection. This adaptive international trial in 50 centers will enroll up to 1540 pts and run on the PRACTICAL platform.